Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease

Letter: infliximab concentrations during induction therapy-one size does not fit all

(2018) K. Papamichael et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn’s Disease

(2018) Kenji Watanabe et al.   Clinical Gastroenterology and Hepatology

Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice

(2017) Mariam Aguas Peris et al.   INFLAMMATORY BOWEL DISEASES

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

(2016) Bella Ungar et al.   Clinical Gastroenterology and Hepatology

Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis

(2016) Konstantinos Papamichael et al.   Clinical Gastroenterology and Hepatology

Efficacy and Safety Profile of Anti–tumor Necrosis Factor-α Versus Anti-integrin Agents for the Treatment of Crohn’s Disease: A Network Meta-analysis of Indirect Comparisons

(2016) Michael Miligkos et al.   CLINICAL THERAPEUTICS

Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohnʼs Disease and Ulcerative Colitis

(2016) Andres J. Yarur et al.   INFLAMMATORY BOWEL DISEASES

Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis

(2016) Konstantinos Papamichael et al.   Journal of Crohns & Colitis

Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn’s Disease

(2016) E. Zittan et al.   Journal of Crohns & Colitis

Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn’s Disease

(2016) Konstantinos Papamichael et al.   Journal of Crohns & Colitis

Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease

(2016) Yukihiro Morita et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-α antibodies in ulcerative colitis

(2016) Yukihiro Morita et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

(2015) L Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis

(2015) Johannan F. Brandse et al.   GASTROENTEROLOGY

Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis

(2014) F. Baert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease

(2014) Y. Mazor et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases

(2014) Xavier Roblin et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease

(2014) Byron P. Vaughn et al.   INFLAMMATORY BOWEL DISEASES

Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases

(2013) Xavier Roblin et al.   Clinical Gastroenterology and Hepatology

Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay

(2013) Shui-Long Wang et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS